FILE PHOTO: The GlaxoSmithKline (GSK) logo is seen on top of GSK Asia House in Singapore, March 21, 2018. REUTERS/Loriene Perera
(Reuters) – GlaxoSmithKline Plc is recalling its heartburn medicine Zantac as a “precautionary measure” due to a probable cancer-causing impurity in the drug, Britain’s medicines watchdog said on Tuesday.
GSK is recalling all unexpired stock of Zantac, also sold generically as ranitidine, from pharmacies as a precaution due to possible contamination with an impurity NDMA, which has genotoxic and carcinogenic potential, the Medicines and Healthcare products Regulatory Agency (MHRA) said.
Reporting by Justin George Varghese in Bengaluru; editing by Bill Berkrot